STOCK TITAN
  1. Home
  2. News
  3. PHAT

Phathom Pharmaceuticals Inc - PHAT STOCK NEWS

Welcome to our dedicated news page for Phathom Pharmaceuticals (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Phathom Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Phathom Pharmaceuticals's position in the market.

News
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Rhea-AI Summary
SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earlier studies. The funding will support the development of registrational data for emactuzumab, aiming to provide a valuable treatment option for patients suffering from TGCT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
clinical trial
-
News
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) will participate in the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024. The management team will engage in a fireside chat and one-on-one meetings during the conference. Investors can access the live webcast and recordings on the company's website for 90 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
-
News
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
Rhea-AI Summary
A national TV and digital media campaign has been launched to educate and inspire millions of people with Erosive Gastroesophageal Reflux Disease (GERD). The campaign aims to raise awareness about the condition and provide resources for those affected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
News
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. reported net revenues of $0.7 million for the fourth quarter of 2023 from the launch of VOQUEZNA® tablets for Erosive GERD. The company achieved strong demand with over 14,000 estimated prescriptions written and secured expanded commercial coverage with a top U.S. pharmacy benefit manager, providing access to approximately 60 million covered lives. Phathom also strengthened its financial position with up to an additional $160 million under an expanded term loan facility, extending the cash runway through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.58%
Tags
earnings
-
News
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (PHAT) to report Q4 and full year 2023 financial results and business progress on March 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences earnings
-
News
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced the addition of VOQUEZNA (vonoprazan) tablets to Express Scripts national formularies for the treatment of Erosive Esophagitis and relief of heartburn, expanding commercial access to an estimated 60 million covered lives in the U.S. The novel treatment is the first FDA-approved potassium-competitive acid blocker for Erosive GERD in over 30 years, addressing patient dissatisfaction with current therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
News
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024, at 1:30 p.m. ET. The company's management team will also have one-on-one meetings during the conference. The live webcast and archived recording of the event can be accessed on the Phathom website. Recordings will be available for 90 days after the meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences
-
News
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announces amendment to term loan facility from Hercules Capital, Inc. (NYSE: HTGC) and Sagard Healthcare, increasing the total loan facility up to $300 million with more favorable terms, including a 14-month extension of the interest-only period and maturity date until December 2027. Cash runway is now expected through the end of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.98%
Tags
none
-
News
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announces FDA acceptance of NDA for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD. The PDUFA target action date is July 19, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
clinical trial
News
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (PHAT) announced the U.S. commercial availability of VOQUEZNA (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB) for the treatment of Erosive Esophagitis and relief of heartburn. VOQUEZNA provides rapid, potent, and durable acid suppression, offering a new and effective treatment option for patients suffering from Erosive GERD. The medication has been shown to provide superior rates of healing and maintenance of healing compared to standard-of-care PPIs, with a distinct mechanism of action and no mealtime dosing burden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Stock PHAT logo
Phathom Pharmaceuticals Inc

Nasdaq:PHAT

PHAT Rankings

#2897 Ranked by Market Cap
#3223 Ranked by Stock Gains
N/A Ranked by Dividends

PHAT Stock Data

592.96M
42.90M
8.81%
87.86%
18.21%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Florham Park

About PHAT

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.